D.E. Shaw & Co
RVMD icon

D.E. Shaw & Co’s Revolution Medicines RVMD Stock Holding History

D.E. Shaw & Co’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.03M Buy
+31,200
New +$3.15M ﹤0.01% 2585

Other funds holding RVMD

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co's RVMD Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Revolution Medicines (RVMD) stake by 37% in Q1 2026, selling an estimated $59.7M and leaving 1,022,298 shares worth $99.4M. The position accounts for 0.06% of the portfolio, ranked #380.

D.E. Shaw & Co first reported a position in RVMD in Q1 2021 and has held it in 17 quarters since. The position peaked at $129M in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

  • D.E. Shaw & Co held 1,022,298 shares of Revolution Medicines worth $99.4M as of Q1 2026.
  • D.E. Shaw & Co sold 591,432 Revolution Medicines shares in Q1 2026, an estimated $59.7M.
  • Revolution Medicines made up 0.06% of D.E. Shaw & Co's portfolio in Q1 2026, its #380 holding.
  • D.E. Shaw & Co first reported a position in Revolution Medicines in Q1 2021 and has held it in 17 quarters since.
  • D.E. Shaw & Co's Revolution Medicines position peaked at $129M in Q4 2025.
  • 512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.